SCHEMBL3529437

SCHEMBL3529437

N#Cc1ccc(OCc2sc(-c3ccc(C(F)(F)F)nc3)nc2CCCOCc2ccccc2)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
MRGPRX4 Q96LA9 2/20 0.37
MAOB P27338 1/20 0.35
PPARD Q03181 4/20 0.33
PPARA Q07869 3/20 0.33
PPARG P37231 2/20 0.33
PTPN1 P18031 3/20 0.33
CNR1 P21554 2/20 0.33
ALOX5AP P20292 1/20 0.32
SCN9A Q15858 1/20 0.32
PRMT5 O14744 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769211 0.82 PPARD (0.45) CYP11B1CYP11B2MAOBPPARDPPARA
SCHEMBL3529390 0.81 PLA2G2A (0.37) PPARDPPARAPPARGPTPN1ALOX5AP
SCHEMBL3769204 0.80 PPARD (0.43) MAOBPPARDPPARAPPARGPTPN1
SCHEMBL3524928 0.80 PPARD (0.45) PPARDPPARAPPARG
SCHEMBL3530562 0.80 HRH4 (0.37) MRGPRX4PPARDPPARAPPARGPTPN1
SCHEMBL13343340 0.80 PLA2G2A (0.36) PPARDPPARAPTPN1ALOX5APPRMT5
SCHEMBL15338115 0.76 PLA2G2A (0.38) PPARDPPARAPPARGPTPN1PRMT5
SCHEMBL3539259 0.75 PPARD (0.42) CYP11B1CYP11B2PPARDPPARAPPARG
SCHEMBL3542725 0.74 PPARD (0.45) MRGPRX4PPARDPPARAPPARGCNR1
SCHEMBL12021633 0.73 PPARD (0.47) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG CYP11B1 55/4885CYP11B2 45/4885MRGPRX4 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.